Scales analysis
Sleep Disturbance
One patient was lost to follow-up in the treatment group because of the local COVID-19. Twenty-four patients completed the follow-up during 24 months of the clinical research. We evaluated clinical improvements among the treatment and control groups using scale data at baseline and the endpoint of 24 months. The scale scores in gross motor function, fine motor function, self-care ability, sociability, expressive ability, and sleep quality showed no apparent differences between the treatment and control groups at baseline (Table Clinical changes of scales between groupsData are summarized as the mean ± SD (standard deviation). GMFM: Gross Motor Function Measure; ADL: Activity of Daily Living; SDSC: Sleep Disturbance Scale for Children; FMFS: Fine Motor Function Scale; SS: Sociability Scale; LAS: Life Adaptability Scale; EAS: Expressive Ability Scale; 24 M: 24 months after treatment*As shown in Table To explore the onset time of NSCs in improving the clinical symptoms of patients with CP and the stability of its therapeutic effect, we further analyzed the evaluation scale data of patients in the treatment group at different time points. We observed a statistically significant increase in all scales except for LAS and GMFM-88-A at different follow-up time points (Table Changes of scales from baseline to month 24 in the treatment groupData are summarized as the mean ± SD (standard deviation). 1 M: 1 month after treatment; 3 M: 3 months after treatment; 6 M: 6 months after treatment; 24 M: 24 months after treatment; GMFM: Gross Motor Function Measure; ADL: Activity of Daily Living; FMFS: Fine Motor Function Scale; SS: Sociability Scale; LAS: Life Adaptability Scale; EAS: Expressive Ability Scale*